Truist says near-term visibility remains challenging for UnitedHealth

Truist noted that UnitedHealth’s (UNH) suspended FY25 guidance is tied to continued elevated utilization pressure in Medicare Advantage, unfavorable impact of new members with indications of pressure in other areas/members with complex conditions which bears watching. Near-term visibility remains challenging and a key area of focus while the company continues to target growth in 2026 and looks to drive Medicare Advantage margin improvement toward its target range through bids reflective of elevated trend, the firm tells investors in a research note. Truist reiterated a Buy rating and $580 price target on UnitedHealth shares.